Reach Pharmaceuticals

Reach Pharmaceuticals is an Australian privately-owned pharmaceutical company established in 2018 with a focus on marketing innovative products with a first-to-market advantage. The company also registers and supplies complex generics and other therapeutic goods based on demand from clinicians. Their pipeline includes thiotepa, potassium citrate, isoprenaline, icatibant, urokinase, carboprost, and romidepsin, among others. Reach Pharmaceuticals has the capabilities to pursue compassionate supplies of products to fulfill shortages and manage the entire process from product identification to sales generation. The company is a leader in the hospital pharmaceuticals space and holds the majority market share for all the products launched to date, whether registered or supplied under compassionate supplies. Additionally, Reach Pharmaceuticals has an interest in the distribution of branded products and has plans to launch new products in the future. The headquarters of Reach Pharmaceuticals is located in Australia. As of now, there is no available information on the last investment or the investors involved. With a strong focus on innovative pharmaceutical products and a significant presence in the hospital pharmaceuticals market, Reach Pharmaceuticals presents an interesting opportunity for potential investors seeking to participate in the pharmaceutical industry.